SCHEMBL6209618

SCHEMBL6209618

CON(C(=O)NOC(=O)Cc1ccccc1)c1cccc(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.47
KMT2A Q03164 3/20 0.45
MEN1 O00255 1/20 0.45
RAB9A P51151 5/20 0.44
NPC1 O15118 3/20 0.44
ALDH1A1 P00352 3/20 0.43
HTT P42858 2/20 0.43
JAK2 O60674 1/20 0.43
PAX8 Q06710 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
SLC7A5 Q01650 1/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
TDP1 Q9NUW8 3/20 0.38
TSHR P16473 1/20 0.38
POLB P06746 1/20 0.37
RECQL P46063 1/20 0.37
LMNA P02545 1/20 0.37
HSP90AA1 P07900 1/20 0.37
PTGIR P43119 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5156830 0.88 TSHR (0.47) L3MBTL1RAB9AALDH1A1SMN1; SMN2SLC7A5
SCHEMBL6208938 0.87 CNR2 (0.41) KMT2AMEN1RAB9ASMN1; SMN2SLC7A5
SCHEMBL6208886 0.85 L3MBTL1 (0.47) L3MBTL1KMT2AMEN1RAB9ANPC1
SCHEMBL6208226 0.74 KMT2A (0.56) L3MBTL1KMT2AMEN1RAB9ANPC1
SCHEMBL5152783 0.73 L3MBTL1 (0.44) L3MBTL1KMT2AMEN1ALDH1A1HTT
SCHEMBL750022 0.71 TSHR (0.51) L3MBTL1KMT2AMEN1RAB9AALDH1A1
Toluene SCHEMBL27935015 0.70 KMT2A (0.57) L3MBTL1KMT2AALDH1A1SMN1; SMN2SLC7A5
SCHEMBL1107144 0.69 SLC7A5 (0.56) L3MBTL1NPC1ALDH1A1SMN1; SMN2SLC7A5
SCHEMBL27516923 0.69 TSHR (0.53) L3MBTL1KMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL29393816 0.68 SMN1; SMN2 (0.61) L3MBTL1KMT2AMEN1ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 EP disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 WO disclosed
EP-1027328-A1 SUBSTITUTED ANILIDES Aventis Pharma Limited (GB) 2000-08-16 EP disclosed
WO-1999023063-A1 SUBSTITUTED ANILIDES AVENTIS PHARMA LIMITED (GB) 1999-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 L3MBTL1 503/4885KMT2A 918/4885MEN1 3022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.